X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (287) 287
Book Review (49) 49
Publication (17) 17
Conference Proceeding (15) 15
Book Chapter (6) 6
Patent (4) 4
Book / eBook (3) 3
Government Document (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (195) 195
humans (189) 189
oncology (124) 124
female (109) 109
middle aged (81) 81
male (73) 73
adult (63) 63
aged (59) 59
cancer (49) 49
chemotherapy (41) 41
abridged index medicus (38) 38
treatment outcome (37) 37
anemia (32) 32
anemia - drug therapy (32) 32
erythropoietin - therapeutic use (32) 32
animals (31) 31
hematology (30) 30
melanoma (30) 30
aged, 80 and over (28) 28
immunotherapy (27) 27
antineoplastic agents - adverse effects (26) 26
quality-of-life (26) 26
recombinant proteins (26) 26
therapy (26) 26
neoplasms - drug therapy (24) 24
anemia - chemically induced (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
breast cancer (22) 22
dendritic cells - immunology (22) 22
medicine, research & experimental (22) 22
mice (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
breast neoplasms - drug therapy (21) 21
double-blind (21) 21
immunology (21) 21
antineoplastic agents - therapeutic use (20) 20
darbepoetin alfa (20) 20
dendritic cells (20) 20
erythropoietin - analogs & derivatives (20) 20
neoplasms - complications (20) 20
research (20) 20
clinical trials (19) 19
colony-stimulating factor (19) 19
erythropoietin (19) 19
epoetin-alpha (18) 18
melanoma - drug therapy (18) 18
melanoma - therapy (18) 18
quality of life (18) 18
recombinant-human-erythropoietin (18) 18
erythropoietin - administration & dosage (17) 17
hematinics - therapeutic use (17) 17
hemoglobin (17) 17
metastatic melanoma (17) 17
neoplasm metastasis (17) 17
breast neoplasms - pathology (16) 16
care and treatment (16) 16
melanoma - immunology (15) 15
cancer-patients (14) 14
dose-response relationship, drug (14) 14
placebo-controlled trial (14) 14
anemia - etiology (13) 13
double-blind method (13) 13
health aspects (13) 13
high-dose chemotherapy (13) 13
mart-1 antigen (13) 13
metastasis (13) 13
prospective studies (13) 13
recombinant proteins - therapeutic use (13) 13
survival (13) 13
article (12) 12
clinical trials as topic (12) 12
drug administration schedule (12) 12
epoetin alfa (12) 12
fatigue (12) 12
medicine, general & internal (12) 12
melanoma - pathology (12) 12
randomized controlled trials as topic (12) 12
time factors (12) 12
antibodies, monoclonal - therapeutic use (11) 11
bone-marrow transplantation (11) 11
drug therapy (11) 11
granulocyte colony-stimulating factor - therapeutic use (11) 11
neoplasm proteins - immunology (11) 11
neoplasm staging (11) 11
neoplasms - therapy (11) 11
survival rate (11) 11
t-lymphocytes - immunology (11) 11
cell line, tumor (10) 10
filgrastim (10) 10
fluorodeoxyglucose f18 (10) 10
hematinics - adverse effects (10) 10
hematology, oncology and palliative medicine (10) 10
medicine (10) 10
neutropenia (10) 10
adenoviridae - genetics (9) 9
analysis (9) 9
antigens, neoplasm - immunology (9) 9
cancer therapies (9) 9
community oncology (9) 9
cytotoxicity, immunologic (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e18300 - e18300
Journal Article
Nature, ISSN 0028-0836, 11/2014, Volume 515, Issue 7528, pp. 568 - 571
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 7, pp. 684 - 685
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2011, Volume 6, Issue 12, pp. e28973 - e28973
Background: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily... 
SIGNALING PATHWAYS | ACTIVATION | THERAPY | CUTANEOUS MELANOMA | BIOLOGY | ACQUIRED-RESISTANCE | MUTATIONS | CELL-LINES | CANCER | OVERCOME | Gene Silencing - drug effects | TOR Serine-Threonine Kinases - metabolism | Humans | Melanoma - enzymology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Mitogen-Activated Protein Kinase Kinases - metabolism | Melanoma - genetics | Inhibitory Concentration 50 | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Rapamycin-Insensitive Companion of mTOR Protein | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Mutation - genetics | Sulfonamides - pharmacology | Sirolimus - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Carrier Proteins - genetics | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Benzimidazoles - pharmacology | Protein Kinase Inhibitors - pharmacology | Ribosomal Protein S6 Kinases - genetics | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | RNA, Small Interfering - metabolism | Development and progression | Genetic engineering | Melanoma | TOR protein | Drugs | Biotechnology | Phosphorylation | Cross-resistance | Clinical trials | Reversing | Raf protein | AKT protein | Drug resistance | Kinases | Skin cancer | Medical research | MEK inhibitors | MAP kinase | Pharmacology | Rapamycin | siRNA | Patients | 1-Phosphatidylinositol 3-kinase | Gene silencing | Signaling | Inhibitors | Cell lines | Mutation | Apoptosis | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2003, Volume 100, Issue 4, pp. 1751 - 1756
Omega-6 (ω-6) polyunsaturated fatty acids (PUFA), abundant in the Western diet, are precursors for a number of key mediators of inflammation including the... 
Unsaturated fatty acids | Biological Sciences | Prostaglandins | Cell growth | 3T3 cells | NIH 3T3 cells | Secretion | Fibroblasts | Cell membranes | Macrophages | Fatty acids
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2014, Volume 4, Issue 1, pp. 80 - 93
Journal Article
2011, 1, Cancer treatment and research, ISBN 9781441970725, Volume 157., xv, 433
This volume reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of hematopoietic growth factors... 
drug therapy | pharmacology | Oncology | Mechanism of action | therapeutic use | Neoplasms | Hematopoietic growth factors | Colony-Stimulating Factors | Clinical & internal medicine | Colony-Stimulating Factors - therapeutic use | Medicine & Public Health | Cancer
Book
Clinical Cancer Research, ISSN 1078-0432, 12/2009, Volume 15, Issue 23, pp. 7116 - 7118
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 654 - 662
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 35, pp. 8968 - 8977
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 7, pp. 1040 - 1050
Purpose The efficacy and safety of darbepoetin alfa (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic... 
SURVIVAL | THERAPY | EFFICACY | ONCOLOGY | TRANSFUSION | RECOMBINANT-HUMAN-ERYTHROPOIETIN | RECEPTOR EXPRESSION | HEMOGLOBIN LEVELS | QUALITY-OF-LIFE | PREVALENCE | EPOETIN-ALPHA
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2009, Volume 15, Issue 19, pp. 6267 - 6276
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 12/2018, Volume 36, Issue 34, pp. 104 - 104
Conference Proceeding